Chemical Proteomics Identifies Druggable Vulnerabilities in a Genetically Defined Cancer

Bar-Peled, Liron, Kemper, Esther K., Suciu, Radu M., Vinogradova, Ekaterina V., Backus, Keriann M., Horning, Benjamin D., Paul, Thomas A., Ichu, Taka-Aki, Svensson, Robert U., Olucha, Jose, Chang, Max W., Kok, Bernard P., Zhu, Zhou, Ihle, Nathan T., Dix, Melissa M., Jiang, Ping, Hayward, Matthew M., Saez, Enrique, Shaw, Reuben J., Cravatt, Benjamin F.·2017·Cell
DOI 10.1016/j.cell.2017.08.051

Cited by (264)

Items 201–264 of 264

  1. Cholesterol as a functional metabolite cooperates with metadherin in cancer cells
    Wen Wang, Xiaolong Liu, Huan Chen, Ting Ling, Tian Xia, Xiumei Liu, Jing L. Liu, Wuxiyar Otkur, Xianzhe Shi, Huan Qi et al. · 2019 · Chinese Chemical Letters
  2. Chemical Proteomics for Expanding the Druggability of Human Disease
    Xiaoyu Zhang · 2020 · ChemBioChem
  3. Chemistry Takes Center Stage for Identifying Cancer Targetability
    Christopher G. Parker, Benjamin F. Cravatt · 2018 · Cell
  4. Activity‐Based Protein Profiling
    Nattawadee Panyain, Cassandra R. Kennedy, Ryan T. Howard, Edward W. Tate · 2019 · Methods and principles in medicinal chemistry
  5. SP3-FAIMS Chemoproteomics for High Coverage Profiling of the Human Cysteinome
    Tianyang Yan, Heta Desai, Lisa M. Boatner, Stephanie Yen, Jian Cao, Maria F. Palafox, Yasaman Jami‐Alahmadi, Keriann M. Backus · 2020 · ChemRxiv
  6. TMEM164 is an acyltransferase that forms ferroptotic polyunsaturated ether phospholipids
    Alex Reed, Timothy B. Ware, Haoxin Li, J. Fernando Bazán, Benjamin F. Cravatt · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  7. An interactive resource mapping the proteome and reactive cysteine landscape across the NCI-60 reveals cell and tissue-specific profiles
    José L. Montaño, Vishnu Rajan Tejus, Vee Xu, Andrew C Condon, Andrew K. Ecker, Andreas Langen, Kevin K. Leung, Balyn W. Zaro · 2025 · Cell chemical biology
  8. Have plastic culture models prevented the discovery of effective cancer therapeutics?
    Kevin M. Tharp · 2024 · British Journal of Pharmacology
  9. CYP4F11, an NRF2 Target Gene, Promotes Hepatocellular Carcinoma Cell Growth
    Jinjing Chen, Carlee A. Trindl, Hong Ye, Dichun Huang, Aikseng Ooi, Joe G. N. Garcia, Eli Chapman, Donna D. Zhang · 2025 · Molecular Carcinogenesis
  10. Enrichable cross-linkers for mapping direct protein interactions
    Ting Wu, Hang-Xu Zhou, Jing Tian, Rong Zhou, Shangwei Huangfu, Bo Jin, Anna A. Sablina, Fangfang Zhou, Hongli Chen, Shibing Tang et al. · 2025 · Genome biology
  11. Combatting resistance: natural products as tools to drive the discovery of untapped antibiotic targets
    Makayla R. Hedges, Camden M. Di Carlo, William M. Wuest · 2025 · Chemical Communications
  12. Novel Biology and Druggable Targets via Chemoproteomics
    Alan Saghatelian · 2017 · Biochemistry
  13. An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human Immune Cells
    Ekaterina V. Vinogradova, Daniel C. Lazar, Radu M. Suciu, Yujia Wang, Giulia Bianco, Yu Yamashita, Vincent M. Crowley, Dave Remillard, Kenneth M. Lum, Gabriel M. Simon et al. · 2019 · SSRN Electronic Journal
  14. The anti-angiogenic compound dimethyl fumarate inhibits the serine synthesis pathway and increases glycolysis in endothelial cells
    María Carmen Ocaña, Chendong Yang, Manuel Bernal, Beatriz Martı́nez-Poveda, Hieu Vu, Casimiro Cárdenas, Ralph J. DeBerardinis, Ana R. Quesada, Miguel Ángel Medina · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
  15. The rise of new targets in melanoma
    Xue Li Bai, Keith T. Flaherty · 2025 · British Journal of Dermatology
  16. Fully‐Functionalized Natural Product Probes to Expand the Chemical Tractability of the Human Proteome
    Christian M. Chaheine, Junchen Tang, Louis Patrick Conway, Christopher G. Parker · 2025 · Angewandte Chemie International Edition
  17. Cysteine Reactivity Profiling Identifies Host Regulators of Mycobacterium tuberculosis Replication in Human Macrophages
    John K. Neff, Kristen E. DeMeester, Paola K. Párraga Solórzano, Radu M. Suciu, Melissa M. Dix, Gabriel M. Simon, Max A. Gianakopoulos, Bruno N. Melillo, Benjamin F. Cravatt, Michael U. Shiloh · 2026 · ACS Infectious Diseases
  18. Context-dependent synthetic lethality — an emerging precision therapeutic approach
    Liang Chang, Katharin L. Shaw, Francisca Vázquez, William R. Sellers · 2026 · Nature reviews. Cancer
  19. Targeting NRF2 addiction in cancer: synthetic lethal strategies beyond direct inhibition
    Melat T. Gebru, David Stokoe · 2026 · Frontiers in Cell and Developmental Biology
  20. Protein State‐Dependent Chemical Biology
    Kevin A. Scott, Tiffany L. Zhang, Sarah Y. Xi, Bryan Ngo, Ekaterina V. Vinogradova · 2023 · Israel Journal of Chemistry
  21. Generating cysteine-trypsin cleavage sites with 2-chloroacetamidine capping
    Samuel Ofori, Heta S. Desai, Flowreen Shikwana, Lisa M. Boatner, Emil R. Dominguez, José O. Castellón, Keriann M. Backus · 2024 · Chemical Communications
  22. Druggable upregulated proteins in EWS-FLI-driven Ewing sarcoma as emerging new therapeutic targets
    Moinuddin Jiauddin · 2025 · American Journal of Translational Research
  23. [A Review of the Redox Regulation of Tumor Metabolism].
    Kui Wang, Hui Ming, Jing Zuo, Hailong Tian, Canhua Huang · 2021 · PubMed Central
  24. Proteome-wide structure-based accessibility analysis of ligandable and detectable cysteines in chemoproteomic datasets
    Matthew E. H. White, Jesús Gil, Edward W. Tate · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  25. Robust proteome profiling of cysteine-reactive fragments using label-free chemoproteomics
    George S. Biggs, Emma E. Cawood, Aini Vuorinen, William J. McCarthy, Harry Wilders, Ioannis G. Riziotis, Antonie J. van der Zouwen, Jonathan Pettinger, Luke Nightingale, Peiling Chen et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
  26. Fully‐Functionalized Natural Product Probes to Expand the Chemical Tractability of the Human Proteome
    Christian M. Chaheine, Junchen Tang, Louis Patrick Conway, Christopher G. Parker · 2025 · Angewandte Chemie
  27. Development of Single‐Molecule Enzyme Activity Assay for Serine Hydrolases Using Activity‐Based Protein Labeling Probes
    Seiya Ishii, Mayano Minoda, Tadahaya Mizuno, Takumi Iwasaka, Hiroyuki Kusuhara, Kazufumi Honda, Yasuteru Urano, Toru Komatsu · 2025 · Small Methods
  28. Heterogeneous expression of immunotherapy response markers in non-small cell lung cancer with hyperactive NRF2 pathway: PD-L1 and beyond
    Karoline Almeida, Marcelo Falchetti, Bárbara dos Santos, Marina Delgobo, Rosângela Mayer Gonçalves, Nauana Somensi, Helena Souza Zancanaro, Juan Nóbrega de Freitas, Raquel Nascimento das Neves, Lisléia Golfetto et al. · 2025 · Redox Biology
  29. Cysteine addiction in drug resistant glioblastoma and therapeutic targeting with designer selenium compounds
    Deanna Marie Tiek, Xiao Song, Runxin Wu, Xiaozhou Yu, Maya N. Walker, Yingyu Mao, Derek Sisbarro, Qiu Qin He, Assa Magassa, Amandeep Singh et al. · 2025 · Neuro-Oncology
  30. Bridging oxidative post-translational modifications to biological meaning
    Maolin Ge, Magdy Gohar, Liron Bar‐Peled, Junbing Zhang · 2026 · Trends in Cell Biology
  31. Aberrant DNA methylation and overexpression of NR0B1 are prognostic biomarkers in KEAP1-mutant lung adenocarcinomas
    Mohamed Elshaer, Ahmed Hammad, Yang Gao, Xiu Jun Wang, Xiuwen Tang · 2025 · Discover Oncology
  32. Recent progress of subcellular-compartment-focused chemical proteomics
    Lei Wang, Hiroshi Nonaka, Itaru Hamachi · 2021 · Elsevier eBooks
  33. Tracking Pathogen Infections by Time‐Resolved Chemical Proteomics
    Ying Zhang, Der‐Shyang Kao, Bing Gu, Rajdeep Bomjan, Mayank Srivastava, Haojie Lu, Daoguo Zhou, W. Andy Tao · 2019 · Angewandte Chemie
  34. Evaluation and Optimization of Chemically-Cleavable Linkers for Quantitative Mapping of Small Molecule-Protein Interactomes
    Adam J. Rabalski, Andrew R. Bogdan, Aleksandra Baranczak · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
  35. Selective inhibitors of JAK1 targeting a subtype-restricted allosteric cysteine
    Madeline E. Kavanagh, Benjamin D. Horning, Roli Khattri, Nilotpal Roy, Justine P. Lu, Landon R. Whitby, Jaclyn C. Brannon, Albert Parker, Joel M. Chick, Christie L. Eissler et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
  36. Oncogenomics/Proteomics of Head and Neck Cancer
    Ruud H. Brakenhoff · 2018 · Springer eBooks
  37. The kinase inhibitor AT9283 selectively kills colorectal cancer cells with hyperactive NRF2
    Laura Torrente, Gunjit Maan, Laura Casares, Angus W. Jackson, Tadashi Honda, Geoffrey Wells, Evgeny Kulesskiy, Jani Saarela, Albena T. Dinkova‐Kostova, Laureano de la Vega · 2019 · bioRxiv (Cold Spring Harbor Laboratory)
  38. Evidence-Based Medicine and Personalized Health Care
    Dirk T. Ubbink, Dink A. Legemate · 2021 · Springer eBooks
  39. Faculty Opinions recommendation of Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16.
    Cheng‐Ming Chiang · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  40. Emergencies/Resuscitation
    Ernst L.W. van Heurn · 2022 · Springer eBooks
  41. Identification of Covalent Ligands – from Single Targets to Whole Proteome
    Chau Ngo, Arunika I. Ekanayake, Chao Zhang · 2023 · Israel Journal of Chemistry
  42. Identification of chemotherapy targets reveals a nucleus-to-mitochondria ROS sensing pathway
    Junbing Zhang, Claire M. Simpson, Jacqueline Berner, Harrison Byron Chong, Jiafeng Fang, Zehra Ordulu, Tommy Weiss‐Sadan, Anthony P. Possemato, Stefan Andrew Harry, Mariko Takahashi et al. · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
  43. Increasing awareness and therapeutical options to improve prognosis of HPV positive and HPV negative head and neck cancer
    Femke Verhees · 2023
  44. Synthesis of non-natural amino acids as covalent inhibitors for protein-protein interactions.
    Siphamandla Austen Dladla · 2023 · ResearchSpace (University of KwaZulu-Natal)
  45. Emerging Technologies for Epigenetic Drug Discovery
    2024 · Royal Society of Chemistry eBooks
  46. Mass Spectrometry and Chemical Biology Approaches for Deconvoluting Epigenetic Targets
    Antony J. Burton, Ghaith M. Hamza, Anthony A. Iannetta, Eric Miele, Andrew X. Zhang · 2024 · Royal Society of Chemistry eBooks
  47. Covalency in PROTACs: Mechanisms and applications
    Thomas M. Geiger, Radosław P. Nowak · 2024 · Annual reports in medicinal chemistry
  48. Nuclear receptor profiling for subtype classification and as prognostic markers in 33 cancer types
    Kazuya Nakamichi, Hironori Suzuki, Yusuke Yamamoto, Kentaro Semba, Jun Nakayama · 2024 · Discover Oncology
  49. Identification of Anticancer ROS Targets by Cysteine Reactivity Protein Profiling
    Junbing Zhang, Liron Bar‐Peled · 2025 · Methods in molecular biology
  50. Illuminating the Ligandable Human Proteome with AI Protein Profiling
    Guy W. Dayhoff, Daniel Kortzak, Mingzhe Shen, Ruibin Liu, Jianping Lin, Zhong‐Yin Zhang, Jana Shen · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  51. LAMB3 regulates ITGB4 to mediate metabolic reprogramming of lung cancer cells, thus promoting the proliferation and metastasis of cancer cells
    Suting Chen, Limin Dong, Zhicheng Ouyang · 2025 · Research Square
  52. NR0B1 alters the 9- cis -retinoic acid response in Ewing Sarcoma cells
    Benjamin D. Sunkel, Meng Wang, Rachel D. Dreher, Melissa C. Sammons, Lindsay Ryan, Amy C. Gross, Scott Friedland, Ryan David Roberts, Emily R. Theisen, Elaine R. Mardis et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  53. On the interface of fatty acid metabolism: A crosstalk between fatty acid ω-hydroxylase CYP4F11 and fatty acid desaturase 2 in non–small cell lung cancer
    Huiting Jia, Simone Brixius‐Anderko · 2025 · Drug Metabolism and Disposition
  54. MAPK Pathway Inhibition Reshapes Kinase Chemical Probe Reactivity Reflecting Cellular Activation States
    Andrew F. Jarvis, Mohd Younis Bhat, Timothé Maujean, Ahlenne L. Abreu, Kaitlyn Toy, George M. Burslem, Donita C. Brady · 2026 · ACS Bio & Med Chem Au
  55. Mapping ortholog-restricted ligandable cysteines in the wheat pathogen Zymoseptoria tritici
    Minjin Yoo, Timothy B. Ware, Sebastián Moschen, Alex Reed, Christopher J. Reinhardt, Evert Njomen, Urvashi Thacker, Bruno N. Melillo, Gabriel Scalliet, Vlad Paşcanu et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  56. 4-Oxo-2-Nonenal Crosslinks Vicinal Cysteine-Lysine Pairs in Cellular Proteins
    Ruifeng Cheng, Minran Wang, Keke Liu, Ling Fu, Ping Xu, Caiping Tian, Jing Hui Yang · 2026 · Molecular & Cellular Proteomics
  57. Oxidized protein states define metastatic fitness in lung cancer
    Maolin Ge, Magdy Gohar, Consuelo Torrini, Yukako Suzuki, Jiang, Yuchen Huang, Benjamin Weinstein, Janice Wong, Naema Nayyar, Md Yousuf Ali et al. · 2026 · bioRxiv (Cold Spring Harbor Laboratory)
  58. Proteogenomic characterization of pulmonary large-cell neuroendocrine carcinoma identifies molecular features and therapeutic strategy
    Lele Zhang, Liangdong Sun, Shengnan Duan, Yilv Yan, Jinyi Song, Linghui Xia, Huansha Yu, Jijun Sun, Junjie Hu, Di Wang et al. · 2026 · Science Advances
  59. A lysis-derived PMSF and orthovanadate oxidant defines a distinct cysteine-engagement profile
    Bethany E. Schaffer, Jung Seung Nam, Ceci A. Cohen, Clementina Mesaros, Robert W. Myers, Leigh A. Baxt, Kathryn E. Wellen, Lewis C. Cantley, Noah Dephoure, Nathaniel W. Snyder et al. · 2026 · Cell chemical biology
  60. BindingDB Entry 50021193: Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update.
    BindingDB · 2025 · UC San Diego
  61. BindingDB Entry 50020650: Cyclopropenone, Cyclopropeniminium Ion, and Cyclopropenethione as Novel Electrophilic Warheads for Potential Target Discovery of Triple-Negative Breast Cancer.
    BindingDB · 2024 · UC San Diego
  62. BindingDB Entry 50020357: Unlocking DCAFs To Catalyze Degrader Development: An Arena for Innovative Approaches.
    BindingDB · 2024 · UC San Diego
  63. BindingDB Entry 50014476: Identification of isoform/domain-selective fragments from the selection of DNA-encoded dynamic library.
    BindingDB · 2022 · UC San Diego
  64. BindingDB Entry 50015450: Novel Electrophilic Warhead Targeting a Triple-Negative Breast Cancer Driver in Live Cells Revealed by "Inverse Drug Discovery".
    BindingDB · 2023 · UC San Diego